Drug intelligence / Profile preview

Exosome liquid dressing

Development stage: Phase 1
Lead developer: Goodain (Beijing) Pharmaceutical Technology
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intrauterine Perfusion

Overview

Exosome liquid dressing, specifically GD007, is an exosome-based therapeutic derived from human induced pluripotent stem cells (iPSCs). Developed by Goodain (Beijing) Pharmaceutical Technology Co., Ltd., this product offers significant advantages over mesenchymal stem cell (MSC)-derived exosomes due to its clonal origin, ensuring superior batch-to-batch consistency and stability. It contains elevated levels of functional factors such as TGF-β (anti-inflammatory) and BDNF (neurotrophic), which contribute to its demonstrated biological effects including anti-apoptosis, inflammation suppression, angiogenesis promotion, fibrosis inhibition, and enhanced tissue repair potential. The drug is being investigated for the treatment of moderate-to-severe intrauterine adhesions (IUA) and has shown preclinical efficacy in models of neuroprotection, epilepsy, and stroke by modulating immune responses and promoting tissue regeneration.

Other names: Human iPSC-Exosome Liquid Dressing

Targets

IL-6 (Interleukin 6)BDNF (Brain-derived neurotrophic factor)TNFA (Tumor necrosis factor alpha (soluble))TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on Exosome liquid dressing.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exosome liquid dressing.

Explore the full profile